Perspective Therapeutics Inc
Research Perspective Therapeutics Inc (CATX) on Bullrun: market cap USD 303.47M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCATX
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 303.47M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 26.79M
- Free cash flow-USD 34.85M
Valuation Snapshot
latest market cap is USD 303.47M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 103.12M | -USD 95.23M | n/a | -1.4 | USD 30.63M | USD 1.63M | USD 207.03M |
| FY2024 | USD 0 | -USD 79.28M | -USD 72.71M | n/a | -1.23 | USD 61.58M | USD 1.68M | USD 290.67M |
| FY2023 | USD 1.43M | -USD 46.51M | -USD 37.99M | 100.0% | -1.74 | USD 9.24M | USD 1.73M | USD 75.18M |
| FY2022 | USD 0 | -USD 10.76M | -USD 10.68M | n/a | -0.5 | USD 20.99M | USD 524.00K | USD 54.64M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 303.47M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 204.43M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 225.44M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 112.23M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 35.53M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 55.40M | n/a | n/a | n/a |
About Perspective Therapeutics Inc
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Related stock research
Other Healthcare stocks
Abbott Laboratories (ABT)
Adagio Medical Holdings Inc (ADGM)
Aethlon Medical Inc (AEMD)
AdaptHealth Corp (AHCO)
Alamar Biosciences, Inc. (ALMR)
Allurion Technologies Inc (ALUR)
Autonomix Medical Inc (AMIX)
Artivion Inc (AORT)
AOTI Inc (AOTI)
Apyx Medical Corp (APYX)
Accuray Inc (ARAY)
Alphatec Holdings Inc (ATEC)
Frequently asked questions
What is Perspective Therapeutics Inc's market cap?
Perspective Therapeutics Inc's market capitalization is USD 303.47M.
What does Perspective Therapeutics Inc do?
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.